Celgene Corp (CELG) 93.79 $CELG
IBD 50 Showing Little Distress, But Few Big Winners
at Investor's Business Daily - Fri Sep 05, 5:45PM CDT
The IBD 50 finds itself with few signs of distress, and a fair share of success stories even as the market's uptrend moderates. It's been a month since the market started climbing from its August lows, and the main indexes have slowed their ascent....
Celgene's Revlimid Impresses in Phase III NDMM Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 05, 3:45PM CDT
Celgene's (CELG) Revlimid performed well in a late-stage study on NDMM.
Midday Glance: Biotechnology companies
AP - Fri Sep 05, 2:45PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are down at 1 p.m.:
Early Glance: Biotechnology companies
AP - Fri Sep 05, 9:12AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are down at 10 a.m.:
Stock Market News for September 05, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Fri Sep 05, 9:10AM CDT
Benchmarks reversed early gains and settled in the red zone on Thursday due to a late sell-off in energy shares
Nuvilex Aims for Market Exclusivity with Orphan Drug Status While Eyeing Larger Cancer Market for Cell-in-a-Box Technology
ACCESSWIRE - Fri Sep 05, 8:06AM CDT
New York, NY / ACCESSWIRE / September 5, 2014 / Nuvilex, Inc. (OTCQB: NVLX) has used the last two weeks to further solidify its position as a biotechnology firm, and to further its treatment for advanced pancreatic cancer, as well as, other abdominal cancers. This summer has been a starting line, of sorts, for Nuvilex to begin making the case that Cell-in-a-Box(r) should help it become a competitor in the cancer market.
Alkermes Completes Enrolment for Phase II ALKS 3831 Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 04, 5:10PM CDT
Alkermes (ALKS) completed enrolling patients in a study on ALKS 3831.
Final Glance: Biotechnology companies
AP - Thu Sep 04, 4:57PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were down at the close of trading:
Watch for Celgene to Potentially Rebound After Falling 1.06% Yesterday
Comtex SmarTrend(R) - Thu Sep 04, 3:52PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $93.70 to a high of $95.39. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $94.26 on volume of 3.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
After Yesterday's Decline of 1.06%, Celgene Offers Investors Better Value
Comtex SmarTrend(R) - Thu Sep 04, 3:52PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $93.70 to a high of $95.39. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $94.26 on volume of 3.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Technical Data on Biotech Stocks - ARIAD Pharma, Tekmira Pharma, Arrowhead Research, Celgene, and Amgen
PR Newswire - Thu Sep 04, 7:55AM CDT
On Wednesday, September 03, 2014, the NASDAQ Composite ended at 4,572.57, down 0.56%, the Dow Jones Industrial Average finished the day 0.06% higher at 17,078.28, and the S&P 500 closed at 2,000.72, down 0.08%. During the trading session, six out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 740.75, up 0.41%, with the index advancing 6.93% in the previous three months. Investor-Edge has initiated coverage on the following equities: ARIAD Pharmaceuticals Inc. (NASDAQ: ARIA), Tekmira Pharmaceuticals Corporation (NASDAQ: TKMR), Arrowhead Research Corporation (NASDAQ: ARWR), Celgene Corporation (NASDAQ: CELG), and Amgen Inc. (NASDAQ: AMGN). Free research on these five companies can be accessed at:
Phase III FIRST(TM) (MM-020/IFM 07-01) Trial of REVLIMID(R) (lenalidomide) Plus Dexamethasone in Newly Diagnosed Multiple Myeloma Patients Who Are Not Candidates for Stem Cell Transplant Published in New England Journal of Medicine
Business Wire - Thu Sep 04, 6:30AM CDT
Celgene Corporation (NASDAQ:CELG) today announced that data from FIRST (MM-020/IFM 07-01)--an open-label phase III randomized study of continuous REVLIMID (lenalidomide) in combination with dexamethasone in patients newly diagnosed with multiple myeloma (NDMM) who are not candidates for stem cell transplant--have been published in the Sept. 4 issue of the New England Journal of Medicine.
Three Stocks Top-Performing Funds Like: Facebook Baidu Gilead
at Investor's Business Daily - Wed Sep 03, 5:28PM CDT
The new buys list of top-performing funds the past three months showed some heavy buying of top-rated stocks. The nation's leading funds have been stocking up on medical issues, which fared well as the market resumed its uptrend in August. Large...
Is It Time to Buy Celgene Corporation's Stock?
Sean Williams, The Motley Fool - Motley Fool - Wed Sep 03, 10:03AM CDT
To put it lightly, Celgene 's stock has been on fire since the recession ended. Since the market bottomed in on March 9, 2009, Celgene shares have returned 376% as of Friday's close. CELG data by YCharts But can Celgene head even...
Bristol-Myers Returns Clazakizumab Rights, Alder Sinks - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 03, 10:02AM CDT
Bristol-Myers' (BMY) decision to opt out of the development process of clazakizumab caused the shares of Alder (ALDR) to plummet significantly.
Bristol-Myers/Pfizer's Eliquis Encourages in VTE Analysis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 02, 5:50PM CDT
Encouraging results on Bristol-Myers /Pfizer's (BMY/PFE) Eliquis was presented from an analysis of a phase III study.
IBD 50 Showing Little Distress, But Few Big Winners
at Investor's Business Daily - Fri Sep 05, 5:45PM CDT
The IBD 50 finds itself with few signs of distress, and a fair share of success stories even as the market's uptrend moderates. It's been a month since the market started climbing from its August lows, and the main indexes have slowed their ascent....
Celgene's Revlimid Impresses in Phase III NDMM Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 05, 3:45PM CDT
Celgene's (CELG) Revlimid performed well in a late-stage study on NDMM.
Midday Glance: Biotechnology companies
AP - Fri Sep 05, 2:45PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are down at 1 p.m.:
Early Glance: Biotechnology companies
AP - Fri Sep 05, 9:12AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are down at 10 a.m.:
Stock Market News for September 05, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Fri Sep 05, 9:10AM CDT
Benchmarks reversed early gains and settled in the red zone on Thursday due to a late sell-off in energy shares
Nuvilex Aims for Market Exclusivity with Orphan Drug Status While Eyeing Larger Cancer Market for Cell-in-a-Box Technology
ACCESSWIRE - Fri Sep 05, 8:06AM CDT
New York, NY / ACCESSWIRE / September 5, 2014 / Nuvilex, Inc. (OTCQB: NVLX) has used the last two weeks to further solidify its position as a biotechnology firm, and to further its treatment for advanced pancreatic cancer, as well as, other abdominal cancers. This summer has been a starting line, of sorts, for Nuvilex to begin making the case that Cell-in-a-Box(r) should help it become a competitor in the cancer market.
Alkermes Completes Enrolment for Phase II ALKS 3831 Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 04, 5:10PM CDT
Alkermes (ALKS) completed enrolling patients in a study on ALKS 3831.
Final Glance: Biotechnology companies
AP - Thu Sep 04, 4:57PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were down at the close of trading:
Watch for Celgene to Potentially Rebound After Falling 1.06% Yesterday
Comtex SmarTrend(R) - Thu Sep 04, 3:52PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $93.70 to a high of $95.39. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $94.26 on volume of 3.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
After Yesterday's Decline of 1.06%, Celgene Offers Investors Better Value
Comtex SmarTrend(R) - Thu Sep 04, 3:52PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $93.70 to a high of $95.39. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $94.26 on volume of 3.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Technical Data on Biotech Stocks - ARIAD Pharma, Tekmira Pharma, Arrowhead Research, Celgene, and Amgen
PR Newswire - Thu Sep 04, 7:55AM CDT
On Wednesday, September 03, 2014, the NASDAQ Composite ended at 4,572.57, down 0.56%, the Dow Jones Industrial Average finished the day 0.06% higher at 17,078.28, and the S&P 500 closed at 2,000.72, down 0.08%. During the trading session, six out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 740.75, up 0.41%, with the index advancing 6.93% in the previous three months. Investor-Edge has initiated coverage on the following equities: ARIAD Pharmaceuticals Inc. (NASDAQ: ARIA), Tekmira Pharmaceuticals Corporation (NASDAQ: TKMR), Arrowhead Research Corporation (NASDAQ: ARWR), Celgene Corporation (NASDAQ: CELG), and Amgen Inc. (NASDAQ: AMGN). Free research on these five companies can be accessed at:
Phase III FIRST(TM) (MM-020/IFM 07-01) Trial of REVLIMID(R) (lenalidomide) Plus Dexamethasone in Newly Diagnosed Multiple Myeloma Patients Who Are Not Candidates for Stem Cell Transplant Published in New England Journal of Medicine
Business Wire - Thu Sep 04, 6:30AM CDT
Celgene Corporation (NASDAQ:CELG) today announced that data from FIRST (MM-020/IFM 07-01)--an open-label phase III randomized study of continuous REVLIMID (lenalidomide) in combination with dexamethasone in patients newly diagnosed with multiple myeloma (NDMM) who are not candidates for stem cell transplant--have been published in the Sept. 4 issue of the New England Journal of Medicine.
Three Stocks Top-Performing Funds Like: Facebook Baidu Gilead
at Investor's Business Daily - Wed Sep 03, 5:28PM CDT
The new buys list of top-performing funds the past three months showed some heavy buying of top-rated stocks. The nation's leading funds have been stocking up on medical issues, which fared well as the market resumed its uptrend in August. Large...
Is It Time to Buy Celgene Corporation's Stock?
Sean Williams, The Motley Fool - Motley Fool - Wed Sep 03, 10:03AM CDT
To put it lightly, Celgene 's stock has been on fire since the recession ended. Since the market bottomed in on March 9, 2009, Celgene shares have returned 376% as of Friday's close. CELG data by YCharts But can Celgene head even...
Bristol-Myers Returns Clazakizumab Rights, Alder Sinks - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 03, 10:02AM CDT
Bristol-Myers' (BMY) decision to opt out of the development process of clazakizumab caused the shares of Alder (ALDR) to plummet significantly.
Bristol-Myers/Pfizer's Eliquis Encourages in VTE Analysis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 02, 5:50PM CDT
Encouraging results on Bristol-Myers /Pfizer's (BMY/PFE) Eliquis was presented from an analysis of a phase III study.
